Public funding for Fibrex

12.08.05 Vienna - Fibrex Medical Research & Development GmbH announces the receipt of public funding for the development of a new sepsis therapy. The Austrian Forschungs-Förderungs-Gesell schaft (FFG) is giving financial support until... more

Patent service to save 30%

12.08.05 Vienna - With the purposeful search for already existing patents the Austrian patent office wants to significantly reduce the number of double patentings. “Many enterprises take the trouble after having invested money... more

Austria

12.08.05 Vienna - Intercell AG has received approval for the start of Phase III clini cal trials of its cell culture-based Japanese Encephalitis vaccine, OC51, in Austria, Australia, Bulgaria, Germany, Romania, the UK, and the USA in... more

Intercell receives NIH grant

10.07.05 Vienna - Austrian vaccine developer Intercell AG has received the largest research grant ever awarded to an Austrian biotech company. The remitter is the National Institute of Health (NIH) of the United States spending a sum of... more

Biopatent Directive implemented

10.07.05 Vienna - With a five-years' delay Austria's National Council has implemented the bio-patent directive of the European Commission into national law. Since the set of rules is highly disputed in Austria only the governing ÖVP/FPÖ... more